39th week of 2009 patent applcation highlights part 34 |
Patent application number | Title | Published |
20090238723 | Multi-modal particle detector - Systems, methods and computer program products for the multi-modal detection of particles are described herein. An embodiment of the present invention is a particle detector that includes a first chamber wherein analyte particles are subjected to a first particle detection mechanism, and a second chamber coupled to the first chamber, wherein the analyte particles are subjected to a second particle detection mechanism, and wherein the detection characteristics of second particle detection mechanism are orthogonal to detection characteristics of the first particle detection mechanism. According to another embodiment, the present invention is a particle detection method including the steps of detecting presence of at least one predetermined particle type in an analyte particle sample using a first particle detection mechanism, and confirming the presence of the predetermined particle type in the analyte particle sample using a second particle detection mechanism, wherein detection characteristics of the second particle detection mechanism are orthogonal to detection characteristics of the first detection mechanism. | 2009-09-24 |
20090238724 | DISC FOR ANALYZING SAMPLE - It is an object of the present invention to provide a disc for analyzing a fluid sample, which can analyze the fluid sample with accuracy by having the fluid sample react quickly and uniformly with the solid reagent held in the chamber. The disc has a chamber is defined by a gap formed with at least two opening, and defined by a spacer intervening between an upper substrate and a lower substrate, the upper substrate having a convex section, the lower substrate having a concave section, the reagent being attached to the concave section of the lower substrate. | 2009-09-24 |
20090238725 | FILTER VIAL - A filter vial and piston are provided where the vial has a cylindrical wall with a closed bottom and open top and with the hollow, tubular piston therein. The piston has a distal end covered by a cup having a proximal cup seal extending outward to engage the walls of the vial to form a fluid tight seal with the vial during use. The distal end of the piston has a piston flange extending outwardly and located adjacent a recess in the piston so the cup forms a snap fit over the piston flange and extends into the recess. The piston flange causes the cup to bulge sufficiently outward to form a fluid tight seal with the vial during use. A filter is placed in the bottom of the cup and abuts an inwardly extending lip on the cup. The filter is held against the lip by a piston support at the distal end of the piston. A cup support at a distal end of the cup also helps support the filter. | 2009-09-24 |
20090238726 | Quantification of analytes using internal standards - The present invention pertains to methods of quantifying the levels of at least one analyte in a sample or extract comprising adding a known quantity of at least one internal standard to the sample or extract. The present invention also relates to internal standards used in mass spectrometry, as well as compositions thereof. Internal standards for mass spectrometry according to the invention can be used, for example, to assist aligning mass spectra obtained from two different samples, each of which comprises the internal standard. In one aspect of the invention, the internal standard is a dendrimer. A labile internal standard may be used in conjunction with the dendrimer. | 2009-09-24 |
20090238727 | MODULAR TEST TUBE RACK - Disclosed herein is a modular test tube rack. The rack contains multiple sub-racks that can be coupled together to form the test tube rack. The sub-rack can be designed to fit into a variety of scientific instrumentation including a fixed rotor centrifuge. The assembled test tube rack can be of a format and size that allows use of standard array pipetters. Thus, a system is provided allowing use of standard array pipetters and high g centrifugation. | 2009-09-24 |
20090238728 | PLASMA SCRUBBER - A plasma scrubber that forms a high temperature atmosphere in a reactor to effectively decompose and remove a non-biodegradable gas and reduce power consumption is disclosed. The plasma scrubber includes: a first reactor to which a non-biodegradable gas is supplied; an electrode installed in the first reactor and protruding in the flow direction of the non-biodegradable gas to generate plasma in the non-biodegradable gas supplied between the electrode and the first reactor by a discharge reaction in the first reactor; a second reactor connected to the first reactor to form continuous arc jets by anchoring the plasma to the electrode; and a third reactor connected to the second reactor to decompose the non-biodegradable gas by forming a reaction section of high temperature that contains electrons and chemical species of high reactivity in the second reactor and thereby increasing the stay time and reactivity of the non-biodegradable gas. | 2009-09-24 |
20090238729 | Conically Shaped Screenless Internals for Radial Flow Reactors - An apparatus for contacting a bed of particulate material with a cross flowing fluid, which maintains the bed of particulate material within a retention volume. The apparatus includes partitions for retaining particles, with apertures disposed within the partitions. The apertures are covered by shrouds that extend above the edges of the apertures to prevent solid particles from spilling through inlet apertures. | 2009-09-24 |
20090238730 | Horizontal Fluidised Bed Reactor - A reactor for contacting a fluid with a granular solid, the reactor including: a reactor housing including a reaction zone in which the fluid and the granular solid are contacted together; a granular solids inlet adapted to deliver a bed of granular solids into the reaction zone wherein the height and/or width dimension of the bed of the granular solids is substantially less than the length of the bed; a plurality of fluid inlets for delivering the fluid into the reaction zone, whereby the delivery of the fluid into the reaction zone at least partially fluidises the bed of granular solids; a granular solids outlet for receiving the bed of granular solids after having passed through the reaction zone; and, a fluid outlet for receiving the fluid, and any entrained particles, after the fluid has passed through the reaction zone. | 2009-09-24 |
20090238731 | SYSTEM AND METHOD FOR ENHANCED REMOVAL OF CO2 FROM A MIXED GAS STREAM - A solvent based flue gas processing system for removing CO | 2009-09-24 |
20090238732 | HONEYCOMB FILTER, EXHAUST GAS PURIFYING APPARATUS AND METHOD FOR MANUFACTURING HONEYCOMB FILTER - A honeycomb filter includes a ceramic block which includes a plurality of honeycomb fired bodies, an adhesive layer, and irregularities on a peripheral face of the ceramic block. Each honeycomb fired body has a longitudinal direction and cell walls extending along the longitudinal direction to define cells each sealed at either one of both ends of each of the cells. The honeycomb fired bodies include at least one of silicon carbide and silicon-containing silicon carbide. The adhesive layer is provided between the honeycomb fired bodies to connect the honeycomb fired bodies. The irregularities on the peripheral face include a projected portion formed by apart of the cell walls. A sealing material layer is provided on the peripheral face of the ceramic block in accordance with the irregularities on the peripheral face so that an outer peripheral surface of the honeycomb filter has surface irregularities thereon. | 2009-09-24 |
20090238733 | HONEYCOMB STRUCTURE, EXHAUST GAS PURIFYING APPARATUS, AND METHOD FOR PRODUCING HONEYCOMB STRUCTURE - A honeycomb structure includes at least one honeycomb member including inorganic fibers and having walls extending along a longitudinal direction to define cells. A catalyst is provided on the wall in an amount of at least about 100 g and at most about 400 g per liter of volume of the honeycomb structure. The honeycomb member has a pore distribution measured using mercury porosimetry in which a pore distribution curve has a first peak in a range from about 0.005 μm to about 0.03 μm of a pore diameter, a second peak in a range from about 1 μm to about 15 μm of the pore diameter, and a third peak in a range from about 15 μm to about 50 μm of the pore diameter, where the curve is drawn by plotting the pore diameter (μm) on an X-axis and a log differential pore volume (mL/g) on a Y-axis. | 2009-09-24 |
20090238734 | SUSCEPTOR WITH ROLL-FORMED SURFACE AND METHOD FOR MAKING SAME - The present invention generally provides apparatus for supporting a large area substrate in a plasma reactor. One embodiment, a substrate support for using in a plasma reactor includes an electrically conductive body has a top surface with a plurality of roll-formed indents. | 2009-09-24 |
20090238735 | System and Method for Extending the Range of Hydrocarbon Feeds in Gas Crackers - In a system for thermal cracking gaseous feedstocks, the system including a gas cracker for producing an effluent comprising olefins, at least one transfer line exchanger for the recovery of process energy from the effluent and a water quench tower system, a process for extending the range of system feedstocks to include liquid feedstocks that yield tar is provided. The process includes the steps of injecting a first quench fluid downstream of the at least one transfer line exchanger to quench the process effluent comprising olefins, separating in a separation vessel a cracked product and a first byproduct stream comprising tar from the quenched effluent, directing the separated cracked product to the water quench tower system and quenching the separated cracked product with a second quench fluid to produce a cracked gas effluent for recovery and a second byproduct stream comprising tar. An apparatus for cracking a liquid hydrocarbon feedstock that yield tar is also provided. | 2009-09-24 |
20090238736 | METHOD FOR MIXING LIQUIDS AND LIQUID MIXING APPARATUS - According to the method of an aspect of the present invention, by forming the laminated body of the liquids by laminating a plurality of liquids after discharging the plurality of liquids from a central portion of the rotational stage onto the rotational stage and rotating the rotational stage after the formation, the centrifugal force by the rotation enables the laminated body to form a thin layer. Accordingly, because the diffusion between the layers can be executed rapidly in the latter mixing process, a mixing of liquids is allowed to advance immediately. | 2009-09-24 |
20090238737 | APPARATUS FOR STERILIZING AND SMOOTHING FINE SANDS - There is provided an apparatus for sterilizing and smoothing fine sands that can reliably sterilize sands through the dispersion of sands without increasing bulk thereof, and can make the shape of sand be optimum for water purification. The apparatus includes a feed chamber | 2009-09-24 |
20090238738 | STERILIZING DEVICE FOR MEDICAL INSTRUMENTS - A sterilizing device for sterilizing at least a portion of a medical instrument including a housing, a reservoir suitable for containing sterilizing agent, a delivery system for conducting the sterilizing agent from the reservoir to a permeable membrane, and a lock out system that blocks access to the permeable membrane when insufficient sterilizing agent is present in the reservoir. In preferred embodiments the delivery mechanism is activatable by pressure applied to the permeable membrane by the at least a portion of the medical instrument (e.g. a head of a stethoscope). | 2009-09-24 |
20090238739 | Sanitizing and dampening container - An apparatus for sanitizing or dampening objects comprising a container having a bottom, a top portion, a front wall, a back wall, and at least one side wall, the side walls extend upwardly from the bottom. Springs are extended downwardly from the side walls or from the front wall and back wall. A grid platform is attached to the springs. The platform is adapted to support the object to be sanitized or dampened. In an alternate embodiment, the container includes a lid structure to be placed inside of the container. The lid structure comprises a top lid portion and side lid portions. The springs are attached and extended downwardly from the top lid portion by the top ends of the spring and the bottom ends of the springs are attached to the grid platform so that the platform is suspended from the lid structure. The object is inserted through the opening on the top lid portion onto the grid platform. The object supported by the grid platform can be lowered into a fluid substance contained in the container by exerting pressure onto the platform. | 2009-09-24 |
20090238740 | METHOD OF REMOVING FLUORIDE IMPURITIES FROM TRONA AND PREPARATION OF SODIUM BICARBONATE - The invention relates to a method of preparing sodium bicarbonate from trona containing sodium fluoride as an impurity comprising preparing a saturated solution of trona and filtering the trona solution to remove insoluble impurities; introducing carbon dioxide to the trona solution till the pH of the solution reaches the range of 7.5 to 8.75 and sodium carbonate in the trona solution is converted to sodium bicarbonate that precipitates; and recovering the precipitated sodium bicarbonate from the trona solution. | 2009-09-24 |
20090238741 | Flying apparatus and method for removing harmful gases from the atmosphere - An apparatus for removing harmful gas components out of the earth's atmosphere is a free-flying autonomous lightweight aircraft with an onboard gas processing system including gas separation or extraction devices, and inlets and outlets connected to the devices. Solar cells and/or thermoelectric generators provided on the craft produce electrical energy to operate the individual devices. The system may include a cryogenic closed-loop circulation system that participates in liquefying the extracted gas components. The apparatus is preferably a lighter-than-air craft like a dirigible. A method of extracting harmful gas components from the atmosphere involves flying the apparatus at a prescribed altitude level and operating the gas processing system to remove the harmful gas component from the atmosphere, then returning the apparatus to earth to offload the liquefied stored harmful gas component. | 2009-09-24 |
20090238742 | SYSTEM AND METHOD FOR ENHANCED REMOVAL OF CO2 FROM A MIXED GAS STREAM VIA USE OF A CATALYST - The proposed invention is directed to a solvent based flue gas processing system for removing CO | 2009-09-24 |
20090238743 | GOLD-SILVER NANOCATALYSTS AND PROCESSES FOR SYNTHESIZING THE SAME - The present invention provides catalysts including similar proportions of gold and silver on a granular support and processes for making the same. Methods of using the catalysts in processes requiring the oxidation of carbon dioxide are also provided. | 2009-09-24 |
20090238744 | Catalyst System for CO-Removal - The invention relates to a catalyst system for the removal of carbon monoxide from a hydrogen containing feed gas. The system includes a first catalyst optimised to selectively oxidize carbon monoxide in the feed gas at temperatures below 100° C. The system also includes a second catalyst, downstream from the first catalyst, optimised to selectively oxidize carbon monoxide in the feed gas at temperatures above 100° C., the second catalyst having a higher carbon monoxide conversion rate than the first catalyst at 100° C. | 2009-09-24 |
20090238745 | Synthesis and Use of AEI Structure-Type Molecular Sieves - A method is disclosed of synthesizing an aluminophosphate or metalloaluminophosphate molecular sieve comprising an AEI structure type material, in which the rate of heating to the crystallization temperature is controlled, either alone or in combination with the H | 2009-09-24 |
20090238746 | PHOSPHORUS RECOVERY METHOD AND PHOSPHORUS RECOVERY SYSTEM - A phosphorus recovery method and a phosphorus recovery system which can make equipment size small, and can be added easily also to an existing wastewater treatment facility, and can recover phosphorus by low cost, are provided. A phosphorus compound adsorption material includes a nitrogen containing compound which has an amino group at an end of molecular structure, a carrier supporting the nitrogen containing compound, and zinc ion or iron ion fixed to the nitrogen containing compound. After passing water to be treated containing phosphorus to an adsorption tower filled up with this phosphorus compound adsorption material to make phosphorus stick to the phosphorus compound adsorption material, a drug solution for desorption is supplied to the adsorption tower, and phosphorus is desorbed in liquid and is recovered. | 2009-09-24 |
20090238747 | PRODUCTION OF OXIDIC NANOPARTICLES - The invention relates to a method for producing (semi)metal oxides and hydroxides, such as Si02, Ti02, Zr02, Zn0 and other (semi)metal salts such as BaSO4, which can be produced by emulsion precipitation in the form of nanoparticles from an aqueous solution. The invention also relates to the use of the same. | 2009-09-24 |
20090238748 | Chlorosilanes purifying apparatus and chlorosilanes manufacturing method - Aluminum chloride from a gas containing chlorosilanes produced in a chlorination reactor is effectively removed. A container | 2009-09-24 |
20090238749 | Method for purification of nitrogen oxide and apparatus for purfication of nitrogen oxide - A nitrogen oxide purifying apparatus includes a gas absorption vessel ( | 2009-09-24 |
20090238750 | INTEGRATED PROCESS FOR THE PRODUCTION OF HYDROGEN FROM HYDROGEN SULPHIDE - A process to efficiently remove sulfur compounds from a hydrocarbon stream in a refinery operation includes the production and recycle of hydrogen from the sulfur compounds. The sulfur compounds present in the hydrocarbon cut are converted to hydrogen sulphide which is split to hydrogen and sulfur in a non-thermal plasma reactor. | 2009-09-24 |
20090238751 | Process Intensification In Microreactors - The present disclosure provides for a chemical reactor which includes elongate chambers defining an arrangement and including first, second, and third elongate chambers adapted to support respective distinct first, second, and third reactor functions associated with respective first, second, and third process feeds, and a distributor arranged in fluidic communication with each of the elongate chambers and for connecting the elongate chambers to at least one fluid source. The distributor is dimensioned to produce a two-dimensional radial distribution of fluidic flow through the first, second, and third elongate chambers with respect to the first, second, and third process feeds. The chemical reactor may further include a monolith catalyst support including an N×M array of channels including the elongated chambers. The elongate chambers and the distributor may manifest an interchangeable cartridge-based system wherein the arrangement of the elongate chambers is selectably detachable from the distributor and replaceable. | 2009-09-24 |
20090238752 | Catalytic Alloy Hydrogen Sensor Apparatus and Process - A process for controlling a refinery or chemical process has been developed. The process comprises flowing a feed stream to a process unit; operating on the feed stream in the process unit to generate an effluent stream; flowing the effluent stream away from the process unit; passing at least a portion of the feed stream or the effluent stream through a catalytic alloy hydrogen sensor and generating a signal corresponding to the concentration of hydrogen present in either the feed stream or the effluent stream; passing the signal to a display unit; and adjusting at least one operating parameter of the process in response to at least the signal generated by the catalytic alloy hydrogen sensor. The catalytic alloy hydrogen sensor may be a palladium-nickel catalytic alloy hydrogen sensor. The adjustments may be based on a calculated mole percent hydrogen. | 2009-09-24 |
20090238753 | Catalytic Alloy Hydrogen Sensor Apparatus and Process - A process for controlling a refinery or chemical process has been developed. The process comprises flowing a feed stream to a process unit; operating on the feed stream in the process unit to generate an effluent stream; flowing the effluent stream away from the process unit; passing at least a portion of the feed stream or the effluent stream through a catalytic alloy hydrogen sensor and generating a signal corresponding to the concentration of hydrogen present in either the feed stream or the effluent stream; passing the signal to a display unit; and adjusting at least one operating parameter of the process in response to at least the signal generated by the catalytic alloy hydrogen sensor. The catalytic alloy hydrogen sensor may be a palladium-nickel catalytic alloy hydrogen sensor. The adjustments may be based on a calculated mole percent hydrogen. | 2009-09-24 |
20090238754 | USE OF PYRENE TO CARRY PEPTIDES ACROSS THE BLOOD BRAIN BARRIER - Described are methods for delivering a peptide agent across the blood-brain barrier, comprising administering to a subject a conjugate comprising (i) a peptide agent and pyrene, and related detection and therapeutic methods. | 2009-09-24 |
20090238755 | Treatment and Diagnosis of Cancer - Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of PSMA. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cells lines, each of which produces a monoclonal antibody recognizing extracellular domains of PSMA of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. | 2009-09-24 |
20090238756 | IMAGE-GUIDED THERAPY OF MYOCARDIAL DISEASE: COMPOSITION, MANUFACTURING AND APPLICATIONS - Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent. | 2009-09-24 |
20090238757 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents - Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities. | 2009-09-24 |
20090238758 | RANDOM AND NON-RANDOM ALKYLENE OXIDE POLYMER ALLOY COMPOSITIONS - A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing. | 2009-09-24 |
20090238759 | Method of Rapid Methylation of Alkene Compound and Kit for PET Tracer Preparation Using the Same - To provide a method of rapid methylation of alkenes, which is applicable to the preparation of a PET tracer and which enables alkenes to be methylated through cross coupling between SP | 2009-09-24 |
20090238761 | Novel Aryl Piperazine Derivatives With Medical Utility - This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D | 2009-09-24 |
20090238762 | Method for treating joint damage - Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods. | 2009-09-24 |
20090238763 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF - The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate. | 2009-09-24 |
20090238764 | DIAGNOSTIC THERAPEUTIC METHOD - A pharmaceutical preparation containing magnetic vesicular particles is disclosed, wherein the magnetic vesicular particles each include magnetic microparticles within a lipid membrane, an organic compound having at least two groups selected from the group consisting of a hydroxyl group, a carboxyl group, a carbamoyl group, an amino group, a mercapto group, a sulfo group, a dithio group, a thiocarboxyl group and a dithiocarboxyl group is bonded to the magnetic microparticle, and the magnetic vesicular particles satisfy the following equation: | 2009-09-24 |
20090238765 | Fluorescent Contrast Agent - The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes. | 2009-09-24 |
20090238766 | BIOLUMINESCENT CONSTRUCT - The invention provides a construct comprising an amino acid sequence attached to a luciferin substrate, wherein the amino acid sequence is not a substrate for either luciferase or caspase-3/7 to render the substrate inactive in the presence of luciferase. The construct is useful, for example, as a negative control for in vitro apoptosis assays and the bioluminescent imaging of drug-induced apoptosis in vivo. The invention also provides methods for screening for novel modulators of an apoptosis-related disease. | 2009-09-24 |
20090238767 | TARGETING CONTRAST AGENTS OR TARGETING THERAPEUTIC AGENTS FOR MOLECULAR IMAGING AND THERAPY - This invention discloses a method of synthesizing targeting contrast agents for molecular imaging and targeting diagnosis and therapy, targeting contrast agents and targeting therapeutic agents and their use. | 2009-09-24 |
20090238768 | MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS - The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS). | 2009-09-24 |
20090238769 | Compositions Comprising Nonionic And Zwittterionic Surfactants - An foaming agent comprising a non-ionic surfactant, zwitterionic surfactant, and free of anionic surfactants which is suitable for use in personal care products, e.g., dentifrice compositions, e.g., for use in the treatment and/or alleviation of xerostomia. | 2009-09-24 |
20090238770 | Organic compounds - A medicament comprising, separately or together, (A) a compound of formula I | 2009-09-24 |
20090238771 | PHARMACEUTICAL FORMULATIONS - An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent comprising said solution is a pleconaril-dissolving glyceride oil, and the solution is suitable for inhalation administration as an aerosol mist. | 2009-09-24 |
20090238772 | METHODS AND COMPOSITIONS FOR PREVENTION OR TREATMENT OF RSV INFECTION - Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets. The siRNA comprises a sense strand of ALN-RSV01 and an antisense strand of ALN-RSV01. | 2009-09-24 |
20090238773 | Use of Morpholino Compounds for the Treatment of Halitosis - Use of a morpholino compound having the general formula (I) wherein R | 2009-09-24 |
20090238774 | Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation - The invention herein relates to the use of nonpathogenic, anti-inflammatory and anti-bleeding lactic acid bacteria strains, and products and methods using such strains for treatment and prophylaxis of bleeding gum and gingivitis caused by oral inflammation. | 2009-09-24 |
20090238775 | MONO-, DI- AND POLYOL ALKOXYLATE PHOSPHATE ESTERS IN ORAL CARE FORMULATIONS AND METHODS FOR USING SAME - This invention relates to a composition useful as an oral care composition comprising an organophosphate material, additional oral care composition ingredients, for example, a surfactant agent, and optionally an abrasive agent. | 2009-09-24 |
20090238776 | Oral Care Compositions and Methods - The present invention relates to oral care compositions. The oral care compositions include an adhesive component and an oral care active, and are combined with a viscosity index improver and/or a water insoluble component. The present invention is also directed to methods relating to the oral care compositions. | 2009-09-24 |
20090238777 | High Fluoride Ion Recovery Compositions - Compositions having high fluoride ion recovery comprising a hydrocolloid, a heteropolysaccharide, a PVME/MA copolymer, and a fluoride ion source and use thereof, e.g., in the treatment of xerostomia and/or sensitive teeth. | 2009-09-24 |
20090238778 | TOOTH WHITENING COMPOSITIONS, DELIVERY SYSTEMS AND METHODS - The present invention is directed to tooth whitening compositions that are capable of being activated by light energy, where the compositions include a safe and effective amount of riboflavin or a derivative of riboflavin, from about 0.1 to about 50 percent by weight of a bleaching agent and a water-soluble liquid phase; to systems for delivering the photoactivatable tooth whitening compositions to the surface of the teeth, and methods of whitening teeth that include the steps of exposing the photoactivatable whitening composition to light energy under conditions effective to photoactivate the tooth whitening composition and maintaining the composition in contact with the teeth under conditions effective to whiten teeth. | 2009-09-24 |
20090238779 | Dental Treatment Compositions and Conformable Dental Treatment Trays Using the Same - The present invention is a formable dental treatment tray utilizing poly(2-ethyl-2-oxazoline) and a gelatinous active. Blending of the active is accomplished by mixing the Poly(2-ethyl-2-oxazoline) with an active ingredient, such as a peroxide like hydrogen peroxide, carbamide peroxide, sodium perborate, or sodium percarbonate, usually also with water or an appropriate organic solvent. Peroxide concentrations in these new gels can reach a 30% concentration of hydrogen peroxide while maintaining a shelf life of six months at room temperature without developing peroxide decomposition. The gels are applied to an appropriate backing and dried to a gelatinous state. In use, the active is hydrated and regains adhesiveness. Then the tray is pressed and formed around a user's dental arch to form the customizable tray. Multiple active ingredients may be used, with or without peroxide, for accomplishing desired treatment regimens. | 2009-09-24 |
20090238780 | Amla extract for transdermal application - An extract of | 2009-09-24 |
20090238781 | POLYGLYCERIN-MODIFIED SILICONE AND A COSMETIC COMPRISING THE SAME - A glycerin-modified silicone represented by the following formula (1): | 2009-09-24 |
20090238782 | COSMETIC COMPOSITION WHICH INCLUDES AT LEAST ONE POLYSACCHARIDE DERIVED FROM BACTERIA OF HYDROTHERMAL ORIGIN - The invention relates to a cosmetic composition which includes at least one polysaccharide derived from bacteria of hydrothermal origin. This polysaccharide can consist of an exopolysaccharide which is derived from fermenting the said bacteria. This composition can be applied, in particular, to everyday care products for all types of skin. | 2009-09-24 |
20090238783 | TREATMENT AND COMPOSITION FOR ACHIEVING SKIN ANTI-AGING BENEFITS BY CORNEUM PROTEASE ACTIVATION - Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing a combination of a cationic surfactant such as N,N,-dimethyldodecyl amine oxide (DMDAO), an anionic surfactant such as sodium dodecyl sulfate (SDS), or monoalkyl phosphate (MAP) and a chelating agent such as ethylene diamine tetraacetate (EDTA) to stimulate a chronic increase in the replacement rate of the skin's stratum corneum by means of corneum protease activation. This chronic, low level stimulation is effective to induce repair and replacement of the stratum corneum, epidermis, and dermis of the skin and improvements in the appearance, function, and anti-aging properties of the skin. | 2009-09-24 |
20090238784 | Novel Unsaturated Fatty Hydroxy Acid Derivatives and the Dermocosmetologic Use Thereof - The invention relates to unsaturated fatty hydroxy acid derivatives of formula (I), wherein R | 2009-09-24 |
20090238785 | Novel Aldehydic Musks and Derivatives Thereof - A compound comprising a Schiffs base of an aldehydic musk aromachemical with a substantially nonvolatile, odorless amine, wherein the imine moiety of said Schiffs base compound is stable against oxidation to a carboxyl group or a mixture of said compounds; said Schiffs base compound being biodegradable over time to said aldehydic musk and said nonvolatile, odorless amine; as well as compositions, products, preparations or articles having improved aroma, fragrance or odor characteristics containing as active ingredient such compound or mixture of compounds; the aldehydic musks themselves, and methods for the preparation of the Schiff bases and methods of imparting fragrance characteristics to substrates. | 2009-09-24 |
20090238786 | COSMETIC FORMULATIONS INCLUDING SOLID ANTIPERSPIRANTS - Cosmetic compositions such as solid antiperspirants and method for their manufacture are described. One such composition includes 1-25 weight percent of an antiperspirant drug active and 10-40 weight percent water. The composition also includes 25-60 weight percent of a humectant and 5-20 weight percent of a fatty acid. The composition also includes 2-10 weight percent of an alkoxylated alcohol and 0.1-10 weight percent of a neutralizer. Other embodiments are described and claimed. | 2009-09-24 |
20090238787 | ODOUR-REDUCING SUBSTANCES - The use is described
| 2009-09-24 |
20090238788 | DELIVERY OF HYDROGELS AS SPRAYS - A method for delivering β-sheet peptide hydrogels to a target surface by shear-thinning and spraying the peptide hydrogel on the surface is provided. The β-sheet peptide hydrogels can be applied over a range of thicknesses and can cover broad surface areas. The β-sheet peptide hydrogels may also include a therapeutic agent. | 2009-09-24 |
20090238789 | Modified erythropoietin polypeptides and uses thereof - Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides. | 2009-09-24 |
20090238790 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections - Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2009-09-24 |
20090238791 | IL-15RALPHA SUSHI DOMAIN AS A SELECTIVE AND POTENT ENHANCER OF IL-15 ACTION THROUGH IL-15BETA/GAMMA, AND HYPERAGONIST (IL-15RALPHA SUSHI - IL-15) FUSION PROTEINS - The present invention relates to the stimulation of the IL-15R beta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha. | 2009-09-24 |
20090238792 | SUPPRESSION OF POSTOPERATIVE ILEUS - The invention provides a method for suppressing postoperative ileus in connection with the performance of a surgical procedure on a patient. In accordance with the inventive method, interleukin-10 (IL-10), glycine, a COX-2 inhibitor and a mast cell stabilizer are administered to the patient undergoing the surgical procedure in an amount and at a location sufficient to therapeutically or prophylactically suppress postoperative ileus in the patient. The invention further provides a pharmaceutically acceptable composition comprising interleukin-10 (IL-10), glycine, a COX-2 inhibitor, a mast cell stabilizer and a pharmaceutically-acceptable carrier. | 2009-09-24 |
20090238793 | TOLL LIKE RECEPTOR (TLR) STIMULATION FOR OCULAR ANGIOGENESIS AND MACULAR DEGENERATION - Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis. | 2009-09-24 |
20090238794 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-09-24 |
20090238795 | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors - A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject. | 2009-09-24 |
20090238796 | Preparation for treatment of non-infectious inflammatory intestinal diseases - The invention relates to medicine and can be used for treating non-infectious inflammatory intestinal diseases to enhance efficiency of the non-infectious inflammatory intestinal disease treatment and reduce the length, the inventive preparation contains 5-aminosalicylic acid (5 ASA) or a substance, which decomposes in the organism that 5 ASA is formed, and a liophylically dried microbial mass of live bifido- or lactobacteria or the mixture, said bacteria can be immobilised on a sorbent. The 5 ASA can be powdered or granulated mesalazine or sulphasalazine. To ease the administration of preparation and ensure the dilution of components in defined sectors of the gastrointestinal tract, said components can be grouped in two capsules that jointly represent a single dose, wherein one capsule contains a microbial mass of live bacteria and the other capsule contains mesalazine or sulphasalazine or the capsule containing microbial mass of live bacteria is arranged in the mesalazine or sulphasalazine-containing capsule. | 2009-09-24 |
20090238797 | NICOTINE-CARRIER VACCINE FORMULATION - The present invention is in the fields of medicine, public health, vaccine and drug formulation. The invention provides composition formulations comprising a nicotine-carrier conjugate and a stabilizer, wherein said stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. The composition formulations are stable after a long time of storage at room temperature. | 2009-09-24 |
20090238798 | Nucleotide Sequences Encoding Insecticidal Proteins - The present invention provides nucleotide sequences encoding an insecticidal protein exhibiting lepidopteran inhibitory activity, as well as a novel insecticidal protein referred to herein as a Cry1A.105 insecticide, transgenic plants expressing the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample. | 2009-09-24 |
20090238799 | Conditionally-Immortalised Pancreatic Cells - Conditionally immortalized pancreatic cells are produced which remain immortal in the presence of 4-hydroxytamoxifen (4-OHT) but express normal pancreatic cell markers when 4-OHT is not present. The cells therefore permit cell lines to be constructed to produce cells useful for transplantation or in screening assays. | 2009-09-24 |
20090238800 | ISOLATION AND THERAPEUTIC APPLICATION OF ADULT RETINAL STEM CELLS COLLECTED FROM EXTRA-RETINAL TISSUES - The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature. The present invention is further directed to a culture medium for growing or maintaining retinal stem cells, and methods of maintaining adult retinal cells in culture. The present invention is further directed to methods of treating a treating an eye with retinal dystrophy using retinal stem cells, and an eye with glaucomatous injury with retinal stem cells. The present invention is further directed to kits for harvesting extra-retinal ocular tissue comprising a sterile container and a harvesting solution, wherein the kit allows the survival of the tissue until later dissociation of cells from the tissue. | 2009-09-24 |
20090238801 | AMNION-DERIVED STEM CELLS AND USES THEREOF - The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stems cells (ADSCs) and to methods of using ADSCs. | 2009-09-24 |
20090238802 | Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 2009-09-24 |
20090238803 | HUMAN CORD BLOOD DERIVED UNRESTRICTED SOMATIC STEM CELLS (USSC) - A composition in human cord and placental blood which comprises unrestricted somatic stem cells is described here which can be amplified in vitro to large quantities sufficient for medical applications as regenerative medicines. Initiation and maintenance as well as ex vivo expansion protocols of such stem cells from cord blood is described. | 2009-09-24 |
20090238804 | USE OF CELLS CONTAINING A SPECIFIC DNA MOLECULE AS CYTOPATHIC AGENTS TO INHIBIT THE PROLIFERATION OF CELLS - The present invention relates to the use of cells containing in their genome a specific DNA molecule, as cytopathic agents able to inhibit the proliferation of cells, when these proliferative cells are contacted with the cells containing the above-mentioned DNA molecule. | 2009-09-24 |
20090238805 | METHODS AND COMPOSITIONS FOR INCREASING RNA INTERFERENCE - The present invention relates to compositions containing a combination of a first active component comprising one or more sulfated polysaccharides and/or glycosaminoglycans and a second active component comprising one or more RNAi-inducing molecules, and methods for using these compositions to enhance double-stranded RNA (dsRNA)-mediated gene silencing in pest or pathogen species. The invention further relates to methods for controlling pests or pathogens, methods for preventing pest infestations or pathogen infections and methods for knocking down gene expression in pests or pathogens using the compositions and methods of the invention. | 2009-09-24 |
20090238806 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION - The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site. | 2009-09-24 |
20090238807 | CELL LINE - The invention provides a cell line complementing HSV ICP4, ICP27, and UL55 genes. | 2009-09-24 |
20090238808 | Process for the identification of novel enzyme interacting compounds - The present invention relates to methods for the characterization of enzymes or of enzyme-compound complexes, wherein the enzyme is obtained from a protein preparation with the help of at least one broad spectrum ligand immobilized on a solid support and wherein the enzyme is characterized by mass spectrometry. These methods are useful for the screening of non-immobilized compound libraries, selectivity profiling of lead compounds and mechanism of action studies in living cells. | 2009-09-24 |
20090238809 | Application Methods to Rapidly Alter Disease and Injury States Using Molecular Transport of B6 - The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity. | 2009-09-24 |
20090238810 | OPHTHALMIC COMPOSITION - An ophthalmic composition is provided which is capable of enhancing a barrier function of a lipid layer that constitutes a tear film, for thereby restricting and curing corneal disorders such as dry eye. It is also an object of the invention to provide the ophthalmic composition with anti-inflammatory and antimicrobial effects for thereby advantageously preventing and easing corneal/conjunctival disorders such as keratoconjunctivitis. In the present invention, apolipoprotein A-1 is included, as an active ingredient, in the ophthalmic composition. | 2009-09-24 |
20090238811 | Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials - Disclosed herein are a coating, a textile finish, a wax, elastomer, a filler, an adhesive, or a sealant, as well as polymeric materials such as a plastic, a laminate, a composite, that includes an enzyme that degrades cell wall or cell membrane components (e.g., a lysozyme, lytic transgrycosylase) alone or in combination with other enzymes such as a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme, or an antimicrobial peptide. Also disclosed herein are methods of retarding or preventing microbial growth on or in a coating, paint, textile finish, wax, elastomer, adhesive, sealant, filler, or a polymeric material, where such a surface material includes an enzyme that degrades cell wall or cell membrane components (e.g., a lysozyme, lytic transgrycosylase). | 2009-09-24 |
20090238812 | Method for the early indentification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery - A method for the early identification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST, specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB. | 2009-09-24 |
20090238813 | Compositions And Methods For Engineered Human Arginine Deiminases - The present invention discloses the engineering of a human enzyme with arginine hydrolytic activity suitable for human therapy. An enzyme comprising of a human sequence is not likely to induce adverse immunological responses and thus is expected to constitute a superior therapeutic. Since the human genome does not encode arginases with the proper high affinity catalytic properties (i.e., for example, a low Km and high catalytic activity, kcat) an appropriate arginase can be engineered by modifying an enzyme with related catalytic activity. For example, the human enzyme PAD4 can hydrolyze arginine in peptide substrates but does not have activity for free arginine. First, a high throughput assay was developed for detecting arginine activity by monitoring the formation of the hydrolytic product citrulline. Then, using a combination of rational design and iterative mutation and screening PAD4 mutants were identified and isolated exhibiting high affinity free arginine metabolic activity. These mutants did not retain activity for their original substrate, peptidyl arginine. | 2009-09-24 |
20090238814 | COMPOSITIONS AND METHODS FOR TREATING HYPOPHOSPHATASIA - The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue. | 2009-09-24 |
20090238815 | Nondegradable Hydrogels For Medical Device Application - Disclosed are nondegradable hydrogels used to coat or form at least a portion of a medical device. The hydrogels may be formed from functionalized PEG based macromers. These hydrogels are easy to sterilize, transport and store. Methods of forming these hydrogels as described herein are included. | 2009-09-24 |
20090238816 | METHOD FOR IMMUNIZING AN AVIAN SPECIES - The present invention relates to a method for generating a plurality of different IgY antibodies, by immunizing each of a plurality of avian organisms of the same or different species with a composition comprising a plurality of different antigens, thereby generating a plurality of different IgY antibodies. | 2009-09-24 |
20090238817 | ANTI-CELL PROLIFERATIVE COMPOUNDS AND METHODS OF USE - The invention provides compounds such as proteins, peptides, peptidomimetics and small molecules, methods for treating cell proliferative disorders such as neoplasia, tumor, or cancer, and metastasis thereof, and methods for identifying and screening for active compounds. | 2009-09-24 |
20090238818 | Induction of Antigen Specific Immunnologic Tolerance - Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types. | 2009-09-24 |
20090238819 | THERAPEUTIC AND DIAGNOSTIC AGENTS - The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signalling (IRS) molecules and which are expressed by cells of haematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter alia as diagnostic markers for cells, targets for cell therapy and as validated drug targets in order to modulate the immune response and to treat, prevent and diagnose a range of diseases conditions including cancer, genetic disease, inflammatory conditions and conditions associated with aberrant haematopoietic cell function or activity. The present invention extends to binding partners of the instant molecules such as, for example, antibodies, ligands, adaptor and other signalling associated molecules, agonists and antagonists and to methods of screening for same. | 2009-09-24 |
20090238820 | ANTI-MAdCAM ANTIBODY COMPOSITIONS - The present invention relates to anti-MAdCAM antibody compositions comprising a chelating agent, and methods of treating inflammatory disease in a subject. | 2009-09-24 |
20090238821 | HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE - A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ. | 2009-09-24 |
20090238822 | Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response - Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HCV core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response. | 2009-09-24 |
20090238823 | Antigen binding proteins capable of binding thymic stromal lymphopoietin - The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders. | 2009-09-24 |